ArticleCancer research2014

Identification of ATR-Chk1 pathway inhibitors that selectively target p53-deficient cells without directly suppressing ATR catalytic activity.

Masaoki Kawasumi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.